In this issue... our top February share tips, company features, market insight & Aggressive Portfolio III.
All hands on Dechra
Shares in Dechra Pharmaceuticals (3836p) were 5325p at the end of 2021 but unfortunately for shareholders, the turn of the year brought about a slide in the company’s valuation. However, we believe that the fall is overdone and the shares now represent good value. Recent interim results provided reassurance and we believe that there is a strong chance that the shares will outperform the market in the coming months.
The company specialises in global veterinary pharmaceuticals and related products…
CONTINUED IN THE FULL NEWSLETTER CLICK TO READ.
